Insider Transactions in Q1 2025 at Natera, Inc. (NTRA)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
9,563
-2.16%
|
$1,319,694
$138.42 P/Share
|
|
Mar 31
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,562
-1.64%
|
$353,556
$138.39 P/Share
|
|
Mar 31
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,404
-0.31%
|
$193,752
$138.4 P/Share
|
|
Mar 28
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+7.78%
|
-
|
|
Mar 28
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+7.41%
|
-
|
|
Mar 28
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+1.09%
|
-
|
|
Mar 28
2025
|
Monica Bertagnolli |
BUY
Grant, award, or other acquisition
|
Direct |
2,877
+50.0%
|
-
|
|
Mar 18
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-1.75%
|
$435,000
$145.97 P/Share
|
|
Mar 18
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.35%
|
$391,500
$145.86 P/Share
|
|
Mar 17
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
792
-0.55%
|
$116,424
$147.8 P/Share
|
|
Mar 17
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
6,702
-3.19%
|
$978,492
$146.03 P/Share
|
|
Mar 17
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
795
-0.25%
|
$116,865
$147.8 P/Share
|
|
Mar 17
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,026
-0.35%
|
$150,822
$147.89 P/Share
|
|
Mar 17
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
928
-0.21%
|
$136,416
$147.89 P/Share
|
|
Mar 17
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
1,127
-0.02%
|
$165,669
$147.8 P/Share
|
|
Mar 17
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
181
-0.07%
|
$26,426
$146.03 P/Share
|
|
Mar 14
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
50,000
-0.42%
|
$7,350,000
$147.39 P/Share
|
|
Mar 12
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,032
+2.72%
|
-
|
|
Mar 12
2025
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
4,000
-8.19%
|
$588,000
$147.76 P/Share
|
|
Mar 12
2025
|
Gail Boxer Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+22.59%
|
$28,000
$7.86 P/Share
|
|
Mar 12
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
6,702
+3.09%
|
-
|
|
Mar 12
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,040
+1.27%
|
-
|
|
Mar 12
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
2,040
+1.38%
|
-
|
|
Mar 12
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,740
+0.77%
|
-
|
|
Mar 12
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Grant, award, or other acquisition
|
Direct |
2,893
+0.12%
|
-
|
|
Mar 12
2025
|
Jonathan Sheena |
BUY
Grant, award, or other acquisition
|
Direct |
411
+0.16%
|
-
|
|
Mar 05
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
87,272
-6.77%
|
$12,479,896
$143.78 P/Share
|
|
Mar 05
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
6,000
-1.02%
|
$858,000
$143.56 P/Share
|
|
Feb 26
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-0.68%
|
$477,000
$159.91 P/Share
|
|
Feb 26
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.21%
|
$429,300
$159.19 P/Share
|
|
Feb 06
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
663
-0.42%
|
$117,351
$177.77 P/Share
|
|
Feb 06
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,632
-1.08%
|
$288,864
$177.77 P/Share
|
|
Feb 05
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,675
+1.06%
|
-
|
|
Feb 05
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
3,197
+1.05%
|
-
|
|
Feb 03
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
43,502
-10.87%
|
$7,656,352
$176.86 P/Share
|
|
Jan 31
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,286
-1.08%
|
$397,764
$174.83 P/Share
|
|
Jan 31
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,720
+10.0%
|
-
|
|
Jan 31
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
36,682
+11.21%
|
-
|
|
Jan 31
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,832
+7.09%
|
-
|
|
Jan 31
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
12,720
+7.9%
|
-
|
|
Jan 31
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,353
+4.43%
|
-
|
|
Jan 31
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Grant, award, or other acquisition
|
Direct |
29,345
+1.2%
|
-
|
|
Jan 31
2025
|
Jonathan Sheena |
BUY
Grant, award, or other acquisition
|
Direct |
3,549
+1.33%
|
-
|
|
Jan 31
2025
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
92
+0.58%
|
-
|
|
Jan 31
2025
|
Roelof Botha |
BUY
Grant, award, or other acquisition
|
Direct |
151
+3.71%
|
-
|
|
Jan 31
2025
|
James Healy |
BUY
Grant, award, or other acquisition
|
Direct |
114
+0.25%
|
-
|
|
Jan 31
2025
|
Herm Rosenman |
BUY
Grant, award, or other acquisition
|
Direct |
133
+0.2%
|
-
|
|
Jan 31
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
163
-0.06%
|
$28,688
$176.6 P/Share
|
|
Jan 29
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,335
-1.01%
|
$719,610
$166.47 P/Share
|
|
Jan 29
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
13,685
-1.29%
|
$2,271,710
$166.61 P/Share
|